Spots Global Cancer Trial Database for tecentriq
Every month we try and update this database with for tecentriq cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1) | NCT02951767 | Bladder Cancer | Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma | NCT02807636 | Urothelial Carc... | Atezolizumab Carboplatin Gemcitabine Placebo Cisplatin | 18 Years - | Hoffmann-La Roche | |
| Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma | NCT02807636 | Urothelial Carc... | Atezolizumab Carboplatin Gemcitabine Placebo Cisplatin | 18 Years - | Hoffmann-La Roche | |
| Derazantinib and Atezolizumab in Patients With Urothelial Cancer | NCT04045613 | Urothelial Carc... | Derazantinib 30... Derazantinib 20... Derazantinib 30... Derazantinib 20... Derazantinib 30... Derazantinib 30... Derazantinib 20... | 18 Years - | Basilea Pharmaceutica | |
| A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | NCT06066138 | Locally Advance... Metastatic Alve... Locally Advance... Metastatic Non ... Locally Advance... Metastatic Smal... Locally Advance... Metastatic Hepa... Locally Advance... Metastatic Mela... | Atezolizumab | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients | NCT06416436 | Solid Tumor | Atezolizumab Stereotactic Ab... | 18 Years - | University of Kansas Medical Center | |
| Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients | NCT06416436 | Solid Tumor | Atezolizumab Stereotactic Ab... | 18 Years - | University of Kansas Medical Center | |
| Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma | NCT05359861 | Hepatocellular ... | SRF388 Atezolizumab Bevacizumab Placebo | 18 Years - | Coherus Biosciences, Inc. | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| ACTolog in Patients With Solid Cancers | NCT02876510 | Cancer Solid Tumor | Fludarabine Cyclophosphamid... IMA101 product Recombinant hum... IMADetect Atezolizumab | 18 Years - 65 Years | Immatics US, Inc. | |
| A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | NCT06066138 | Locally Advance... Metastatic Alve... Locally Advance... Metastatic Non ... Locally Advance... Metastatic Smal... Locally Advance... Metastatic Hepa... Locally Advance... Metastatic Mela... | Atezolizumab | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1) | NCT02951767 | Bladder Cancer | Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| Derazantinib and Atezolizumab in Patients With Urothelial Cancer | NCT04045613 | Urothelial Carc... | Derazantinib 30... Derazantinib 20... Derazantinib 30... Derazantinib 20... Derazantinib 30... Derazantinib 30... Derazantinib 20... | 18 Years - | Basilea Pharmaceutica | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors | NCT04116320 | Melanoma Breast Cancer Merkel Cell Car... Squamous Cell C... Non Small Cell ... Cervical Cancer Urothelial Carc... Ovarian Cancer Hepatocellular ... Small-cell Lung... Microsatellite ... Gastric Cancer Esophageal Canc... | Echopulse Poly ICLC Standard of Car... | 18 Years - | University of Virginia | |
| Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients | NCT05703971 | Small Cell Lung... | quaratusugene o... atezolizumab | 18 Years - | Genprex, Inc. | |
| A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | NCT06066138 | Locally Advance... Metastatic Alve... Locally Advance... Metastatic Non ... Locally Advance... Metastatic Smal... Locally Advance... Metastatic Hepa... Locally Advance... Metastatic Mela... | Atezolizumab | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma | NCT05359861 | Hepatocellular ... | SRF388 Atezolizumab Bevacizumab Placebo | 18 Years - | Coherus Biosciences, Inc. | |
| A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1) | NCT02951767 | Bladder Cancer | Atezolizumab | 18 Years - | Hoffmann-La Roche |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
